Journey Medical Corp (DERM)
NASDAQ:DERM
Want to see DERM full AI Analyst Report?
DERM Stock Chart & Stats
$5.39
-$0.02(-0.58%)
At close: 4:00 PM EST
$5.39
-$0.02(-0.58%)
Day’s Range― - ―
52-Week Range$4.31 - $9.56
Previous CloseN/A
Volume25.59K
Average Volume (3M)296.62K
Market Cap
$173.74M
Enterprise Value$171.91M
Total Cash (Recent Filing)$27.22M
Total Debt (Recent Filing)$25.47M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 11, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding21,534,548
10 Day Avg. Volume196,071
30 Day Avg. Volume296,618
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)5.93
Price to Sales (P/S)3.05
P/FCF Ratio-15.18
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue2.66
Enterprise Value/Gross Profit4.40
Enterprise Value/Ebitda-95.40
Forecast
1Y Price Target
$13.50Price Target Upside150.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.07
Revenue Forecast (FY)$84.75M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Product AdoptionSustained top-line growth driven by Emrosi indicates accelerating product adoption and market traction. Rising prescriptions and prescriber counts signal product-market fit and expanding commercial reach, supporting durable revenue scalability and improved operating leverage over the next several quarters.
Payer & GPO Coverage ExpansionBroader GPO and PBM-affiliated coverage materially increases addressable commercial lives and reduces distribution friction. This structural access supports formulary adoption, steadier demand and reduced reliance on temporary copay support, improving predictability of revenue as payer work progresses.
Improving Profitability MetricsA swing to positive adjusted EBITDA and narrowing GAAP losses reflect operating leverage beginning to materialize. Controlled SG&A and modest expense growth alongside revenue scale point to the potential for sustained profitability expansion and cash generation if topline and margin trends continue.
Bears Say
Negative Cash Flow & BurnPersistent negative operating and free cash flow increases dependence on external financing and limits strategic optionality. Until operating cash turns sustainably positive, the company faces heightened refinancing, dilution or interest-cost risk which could constrain investment in commercial expansion.
Rising LeverageA sharp increase in leverage raises fixed obligations and reduces balance-sheet flexibility. If margin volatility or slower payer uptake occurs, higher debt amplifies downside risk, increases interest burden and narrows room for strategic investments or absorptions of one-time charges.
Concentration & Payer Coverage GapsHeavy reliance on Emrosi as the primary growth engine paired with limited high-quality payer coverage means revenue expansion depends on formulary upgrades. This creates execution risk and exposure to ASP volatility and reimbursement timing across the 18–24 month post-launch window.
Journey Medical Corp News
DERM FAQ
What was Journey Medical Corp’s price range in the past 12 months?
Journey Medical Corp lowest stock price was $4.31 and its highest was $9.55 in the past 12 months.
What is Journey Medical Corp’s market cap?
Journey Medical Corp’s market cap is $173.74M.
When is Journey Medical Corp’s upcoming earnings report date?
Journey Medical Corp’s upcoming earnings report date is Aug 11, 2026 which is in 72 days.
How were Journey Medical Corp’s earnings last quarter?
Journey Medical Corp released its earnings results on May 13, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.088 by $0.008.
Is Journey Medical Corp overvalued?
According to Wall Street analysts Journey Medical Corp’s price is currently Undervalued.
Does Journey Medical Corp pay dividends?
Journey Medical Corp does not currently pay dividends.
What is Journey Medical Corp’s EPS estimate?
Journey Medical Corp’s EPS estimate is -0.02.
How many shares outstanding does Journey Medical Corp have?
Journey Medical Corp has 21,534,548 shares outstanding.
What happened to Journey Medical Corp’s price movement after its last earnings report?
Journey Medical Corp reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.088. Following the earnings report the stock price went up 22.351%.
Which hedge fund is a major shareholder of Journey Medical Corp?
Currently, no hedge funds are holding shares in DERM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Journey Medical Corp Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (150.46% Upside)
$13.50 (150.46% Upside)
Blogger Sentiment
Bullish
DERM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.76%
12-Months-Change
Fundamentals
Return on Equity
-35.57%
Trailing 12-Months
Asset Growth
7.74%
Trailing 12-Months
Company Description
Journey Medical Corp
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
DERM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for Emrosi and meaningful financial improvement: robust revenue growth (total revenue +21% YoY; Emrosi revenue +~200% YoY), rising prescription volumes and prescriber counts, swing to positive adjusted EBITDA, and improved cash balance. Key execution wins include contracts with the three major PBM-affiliated GPOs and expanding clinical validation. Remaining execution items and risks include gross-margin pressure from a one-time API write-down, variability in revenue-per-script/ASP as payer coverage matures, limited current quality coverage (single-step or better ~34% of commercial lives), and an ongoing GAAP net loss. Overall, positive operational and financial trajectory but with clear near-term tasks on payer adoption and margin stability.View all DERM earnings summariesDERM Stock 12 Month Forecast
Average Price Target
$13.50
▲(150.46% Upside)
Technical Analysis
Talphera
―
Assertio Therapeutics
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Alpha Teknova
―
Ownership Overview
19.18% Insiders
14.60% Mutual Funds
32.16% Other Institutional Investors
25.52% Public Companies and
Individual Investors